Annual Cash & Cash Equivalents
$82.25 M
-$42.53 M-34.08%
December 31, 2023
Summary
- As of February 7, 2025, ESPR annual cash & cash equivalents is $82.25 million, with the most recent change of -$42.53 million (-34.08%) on December 31, 2023.
- During the last 3 years, ESPR annual cash & cash equivalents has fallen by -$222.71 million (-73.03%).
- ESPR annual cash & cash equivalents is now -73.03% below its all-time high of $304.96 million, reached on December 31, 2020.
Performance
ESPR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$144.72 M
-$44.59 M-23.55%
September 30, 2024
Summary
- As of February 7, 2025, ESPR quarterly cash and cash equivalents is $144.72 million, with the most recent change of -$44.59 million (-23.55%) on September 30, 2024.
- Over the past year, ESPR quarterly cash and cash equivalents has dropped by -$44.59 million (-23.55%).
- ESPR quarterly cash and cash equivalents is now -52.55% below its all-time high of $304.96 million, reached on December 31, 2020.
Performance
ESPR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ESPR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -34.1% | -23.6% |
| 3 y3 years | -73.0% | -23.6% |
| 5 y5 years | +122.5% | -31.7% |
ESPR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -60.6% | at low | -36.1% | +76.0% |
| 5 y | 5-year | -73.0% | at low | -52.5% | +76.0% |
| alltime | all time | -73.0% | +5135.1% | -52.5% | +2122.5% |
Esperion Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $144.72 M(-23.6%) |
| Jun 2024 | - | $189.30 M(-16.5%) |
| Mar 2024 | - | $226.61 M(+175.5%) |
| Dec 2023 | $82.25 M(-34.1%) | $82.25 M(-28.4%) |
| Sep 2023 | - | $114.83 M(-17.1%) |
| Jun 2023 | - | $138.47 M(-4.4%) |
| Mar 2023 | - | $144.91 M(+16.1%) |
| Dec 2022 | $124.78 M(-40.3%) | $124.78 M(-21.7%) |
| Sep 2022 | - | $159.40 M(+29.7%) |
| Jun 2022 | - | $122.94 M(-18.2%) |
| Mar 2022 | - | $150.36 M(-28.0%) |
| Dec 2021 | $208.89 M(-31.5%) | $208.89 M(+101.5%) |
| Sep 2021 | - | $103.67 M(-52.7%) |
| Jun 2021 | - | $219.19 M(+0.6%) |
| Mar 2021 | - | $217.94 M(-28.5%) |
| Dec 2020 | $304.96 M(+83.6%) | $304.96 M(+41.4%) |
| Sep 2020 | - | $215.75 M(-27.7%) |
| Jun 2020 | - | $298.49 M(+99.8%) |
| Mar 2020 | - | $149.39 M(-10.1%) |
| Dec 2019 | $166.13 M(+349.3%) | $166.13 M(-21.6%) |
| Sep 2019 | - | $211.98 M(-22.7%) |
| Jun 2019 | - | $274.34 M(+56.9%) |
| Mar 2019 | - | $174.84 M(+372.9%) |
| Dec 2018 | $36.97 M | $36.97 M(+38.2%) |
| Sep 2018 | - | $26.75 M(+9.7%) |
| Jun 2018 | - | $24.38 M(-20.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $30.82 M(-10.6%) |
| Dec 2017 | $34.47 M(-9.7%) | $34.47 M(+63.9%) |
| Sep 2017 | - | $21.02 M(+3.2%) |
| Jun 2017 | - | $20.37 M(+2.5%) |
| Mar 2017 | - | $19.87 M(-47.9%) |
| Dec 2016 | $38.16 M(-50.7%) | $38.16 M(-19.0%) |
| Sep 2016 | - | $47.14 M(-3.3%) |
| Jun 2016 | - | $48.77 M(+31.1%) |
| Mar 2016 | - | $37.21 M(-51.9%) |
| Dec 2015 | $77.34 M(-9.1%) | $77.34 M(-4.3%) |
| Sep 2015 | - | $80.82 M(-37.7%) |
| Jun 2015 | - | $129.79 M(-37.8%) |
| Mar 2015 | - | $208.64 M(+145.4%) |
| Dec 2014 | $85.04 M(+50.4%) | $85.04 M(+111.4%) |
| Sep 2014 | - | $40.23 M(-16.1%) |
| Jun 2014 | - | $47.94 M(-1.4%) |
| Mar 2014 | - | $48.64 M(-14.0%) |
| Dec 2013 | $56.54 M(+768.3%) | $56.54 M(-21.4%) |
| Sep 2013 | - | $71.90 M(+332.4%) |
| Jun 2013 | - | $16.63 M(-20.4%) |
| Mar 2013 | - | $20.89 M(+220.8%) |
| Dec 2012 | $6.51 M(+314.5%) | $6.51 M |
| Dec 2011 | $1.57 M(-96.1%) | - |
| Dec 2002 | $40.50 M(-42.4%) | - |
| Dec 2001 | $70.29 M(+0.1%) | - |
| Dec 2000 | $70.23 M(+1089.5%) | - |
| Dec 1999 | $5.90 M | - |
FAQ
- What is Esperion Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Esperion Therapeutics?
- What is Esperion Therapeutics annual cash & cash equivalents year-on-year change?
- What is Esperion Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Esperion Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ESPR is $82.25 M
What is the all time high annual cash & cash equivalents for Esperion Therapeutics?
Esperion Therapeutics all-time high annual cash & cash equivalents is $304.96 M
What is Esperion Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ESPR annual cash & cash equivalents has changed by -$42.53 M (-34.08%)
What is Esperion Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ESPR is $144.72 M
What is the all time high quarterly cash and cash equivalents for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly cash and cash equivalents is $304.96 M
What is Esperion Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ESPR quarterly cash and cash equivalents has changed by -$44.59 M (-23.55%)